Corcept Therapeutics Inc

Corcept insider Guyer buys 20k shares at $21.65—deep‑discount to $52—while selling options, hinting confidence in cortisol‑drug pipeline and potential upside.

Corcept insider buys reveal executive confidence amid legal risk, showing disciplined buying and long‑term optimism for investors.

CEO Joseph Belanoff sells 26k Corcept shares via a pre‑planned 10b5‑1 plan, after FDA approval of Lifyorli, yet the move signals routine liquidity, not a sell‑off.

Corcept insider trading: Guyer William’s recent buy‑sell cycle signals confidence and strategic liquidity management, hinting at potential upside if the pipeline progresses.

Insider moves in Corcept Therapeutics reveal portfolio rebalancing, not a red flag, amid muted market reaction and growing social‑media buzz.

James Wilson’s recent sale of 28,000 Corcept Therapeutics shares shows insiders are rebalancing, not signaling a downturn, amid a 15% monthly dip and a potential rebound from new drug pipeline progress.

Insider buying shows confidence in Corcept amid legal and market turmoil—2026 trades signal a stabilizing factor for investors navigating FDA and fraud challenges.

Corcept Therapeutics’ insider buying surge—140K shares per exec—signals confidence amid a steep 41% dip and class‑action lawsuit; investors weigh optimism vs. risk.

Corcept insider Wilson buys 100,000 shares amid earnings miss and regulatory hurdles, signaling cautious confidence in its Cushing’s drug pipeline.